Real-world analysis of treatment patterns examining nab-Paclitaxel plus Gemcitabine (nab-P+G) versus FOLFIRINOX (FFX) in first-line (1L) treatment (tx) of metastatic pancreatic adenocarcinoma (MPAC) in a U.S. community oncology setting.

Fadi S. Braiteh,Manish Patel,Monika Parisi,Quanhong Ni,Si yeon Park,Claudio Faria

Journal of Clinical Oncology（2016）

引用 0|浏览0

暂无评分

摘要

e18130Background: In independent phase III trials, both nab-P + G and FFX demonstrated significantly better OS, PFS, and ORR than G alone as 1L tx for MPAC. Limited real-world data exist on the eff...

查看译文

关键词

metastatic pancreatic adenocarcinoma,real-world,nab-paclitaxel,first-line

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要